<DOC>
	<DOCNO>NCT02132117</DOCNO>
	<brief_summary>This study evaluate safety efficacy oxymetazoline hydrochloride ( HCl ) cream 1.0 % ( AGN-199201 ) daily compare vehicle treatment persistent moderate severe facial erythema associate rosacea .</brief_summary>
	<brief_title>Safety Efficacy Oxymetazoline HCl Cream 1.0 % Patients With Persistent Erythema Associated With Rosacea</brief_title>
	<detailed_description />
	<mesh_term>Rosacea</mesh_term>
	<mesh_term>Erythema</mesh_term>
	<mesh_term>Oxymetazoline</mesh_term>
	<mesh_term>Phenylephrine</mesh_term>
	<criteria>Moderate severe persistent facial erythema associate rosacea . Greater 3 inflammatory lesion face Current treatment monoamine oxidase ( MAO ) inhibitors Raynaud 's syndrome , narrow angle glaucoma , orthostatic hypotension , scleroderma Sjogren 's syndrome .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>